Letter by Ren et al Regarding Article, “Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study”
Authors:
- 15 September 2020
- journal article
- letter
- Published by Wolters Kluwer Health in Circulation
- Vol. 142 (11) , E156-E157
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast CancerCirculation, 2020
- Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trialThe Lancet, 2020
- Cardiovascular Disease After Aromatase Inhibitor UseJAMA Oncology, 2016
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trialsThe Lancet, 2015
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused UpdateJournal of Clinical Oncology, 2014